Abstract
BackgroundGlucocorticoids (GCs) and disease-modifying agents (DMARDs) are frequently used in the management of juvenile-onset Systemic Lupus Erythematosus (JSLE). Whilst affecting a range of immune cells including neutrophils, impact of these...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
